Full Breakdown
Efficacy and Safety of Higher Doses of Semaglutide for Weight Loss
9/21/2025, 11:13:02 AM
Overview of Clinical Trials
Recent studies published in *The Lancet Diabetes & Endocrinology* have demonstrated that higher doses of semaglutide, specifically a 7.2 mg weekly regimen, are more effective for weight loss compared to standard doses. Conducted between January 2023 and November 2024 across 95 medical facilities in 11 countries, the trials involved 1,407 participants with obesity but no type 2 diabetes. Participants receiving the higher dose lost an average of 19% of their body weight, compared to 16% for those on a 2.4 mg dose and nearly 4% for the placebo group. Notably, about 50% of the higher dose group lost at least 20% of their body weight.
A second trial, involving 512 participants diagnosed with both obesity and type 2 diabetes, reported similar findings. Participants on the 7.2 mg dose experienced significant reductions in waist size and blood sugar levels, although gastrointestinal side effects were noted, which were manageable for most.
Expert Perspectives
Experts in the field have expressed optimism regarding the findings. Dr. Dan Azagury, a bariatric surgeon at Stanford University, highlighted that the new dosing of semaglutide offers a more effective option while maintaining a tolerable side effect profile. However, he raised concerns about an increase in dyseasthesia, a condition characterized by skin sensitivity, which was reported in 22.9% of participants on the higher dose compared to 6% on the lower dose.
Dr. Mir Ali, a general surgeon, emphasized that while GLP-1 weight loss drugs like semaglutide are effective, bariatric surgery remains a superior option for those who qualify, offering more significant long-term benefits.
Comparison with Weight Loss Surgery
A separate study conducted by the Cleveland Clinic, published in *Nature Medicine*, found that weight-loss surgery outperformed GLP-1 drugs in terms of weight loss, longevity, and reduction of serious health complications. The study tracked nearly 4,000 participants, revealing that those who underwent surgery lost an average of 22% of their body weight over ten years, compared to just under 7% for those on GLP-1 medications. Additionally, surgery was linked to lower rates of heart disease, kidney issues, and diabetes-related complications.
Dr. Ali Aminian, the study's senior researcher, stated, “Even with today’s best medicines, metabolic surgery offers unique and lasting benefits for people with obesity and diabetes.” This suggests that while semaglutide is effective, it may not provide the same long-term health advantages as surgical options.
Official Statements & Responses
Novo Nordisk, the manufacturer of semaglutide, has submitted a New Drug Application to the FDA for an oral version of the medication, which could expand treatment options for those who prefer not to use injections. The company anticipates a decision by the end of the year. Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, noted that the oral formulation could address patient preferences for non-injection therapies.
Conflicting Reports & Gaps
While the studies indicate promising results for higher doses of semaglutide, there are concerns regarding the long-term safety and efficacy of these dosages. Experts have called for further research to assess potential risks associated with prolonged use of higher doses, particularly regarding the management of side effects.
Conclusion
The emerging data on higher doses of semaglutide presents a significant advancement in weight management strategies for individuals with obesity. However, the comparative effectiveness of surgical interventions highlights the need for personalized treatment approaches. As the FDA reviews the oral semaglutide application, the landscape of obesity treatment continues to evolve, offering new hope for those seeking effective weight loss solutions.
